Print this page
-
A Prospective Randomized Study of Ramucirumab plus Pembrolizumab versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer.
Protocol: 032304Principal Investigator:
- Missak Haigentz MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Lung -
Phase 2 Randomized Clinical Trial Comparing the Safety and Efficacy of PULSAR-Integrated Radiotherapy + Pembrolizumab or Nivolumab Administered with or without STING-Agonist IMSA101 in Patients with Oligometastatic Non-Small Cell Lung Cancer and Renal Cell Carcinoma
Protocol: 152302Principal Investigator:
- Matthew Deek (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Lung
Other Urinary -
CTEP #10512: A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer
Protocol: 032309Principal Investigator:
- Salma Jabbour M.D. (Rutgers University)
Applicable Disease Sites: Lung -
TELEhealth Shared decision-making COaching for lung cancer screening in Primary carE (TELESCOPE).
Protocol: 132207Principal Investigator:
- Anita Kinney PhD,RN (Rutgers University)
Applicable Disease Sites: Lung -
Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated with Chemoradiation Therapy: A Prospective Longitudinal Cohort.
Protocol: 152101Principal Investigator:
- Salma Jabbour M.D. (Rutgers University)
Applicable Disease Sites: Lung